Precigen (PGEN)
(Delayed Data from NSDQ)
$1.55 USD
0.00 (0.00%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $1.55 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PGEN 1.55 0.00(0.00%)
Will PGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PGEN
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
PGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
Other News for PGEN
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
6 Analysts Assess Precigen: What You Need To Know
Precigen stock rallies 17% on data for PRGN-2012 gene therapy
H.C. Wainwright Keeps Their Buy Rating on Precigen (PGEN)